Pure Global AI
NCT06243835Not yet recruiting

A Study to Test the Effects of Kindolor at Different Doses in Healthy Adults

A Phase 1a Randomized, Double-blind, Placebo-controlled, Single Site, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Kindolor Tosylate in Healthy Adults
Lohocla Research CorporationPhase 1ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Chronic Pain
Drug/Device/Intervention
Kindolor Tosylate
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Lohocla Research Corporation
Location
La Jolla, United States of America
Timeline & enrollment
Phase
Phase 1
Start date
Apr 01, 2024
End date
Nov 30, 2024
Enrollment
32 participants
Primary outcome

Incidence, Severity and Relationship of Adverse Events [Safety and Tolerability]

Summary

The goal of this study is to test Kindolor in healthy adults. The main questions it aims to
 answer are:
 
 - What is the safe dose of Kindolor in healthy volunteers?
 
 - How is Kindolor metabolized by the human body?
 
 Participants will undergo medical tests before and after receiving Kindolor or a placebo to
 see if there is any difference between the groups.

ICD-10 classifications
Other chronic painChronic intractable painPain, not elsewhere classifiedPain, unspecifiedPain associated with micturition
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06243835
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06243835 through Pure Global AI's free database. This Phase 1 trial is sponsored by Lohocla Research Corporation and is currently Not yet recruiting. The study focuses on Chronic Pain. Target enrollment is 32 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.